This fixed-dose combination formulation comprises telmisartan and hydrochlorothiazide, primarily indicated for the treatment of essential hypertension. It is a mainstream antihypertensive combination therapy recommended by authoritative domestic and international guidelines. This product has successfully passed the national bioequivalence assessment for generic medicines.

Primary Indications

Primary hypertension

The Main Contraindication To Medication

Individuals with hypersensitivity to the active ingredient or any excipients of this product; those with hypersensitivity to other sulphonamide derivatives (as hydrochlorothiazide is a sulphonamide derivative); during the second and third trimesters of pregnancy and during lactation; cholestatic disorders and biliary tract obstructive diseases; Severe hepatic or renal impairment; refractory hypokalaemia or hypercalcaemia;

Dosage Form

Tablet